Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers November 7, 2019
Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019 July 31, 2019
Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019 June 24, 2019
